Irwin Naturals' Bold Leap: Cannabis, Psychedelics Drive Q3 Buzz Despite Falling Revenue & Surging Losses
Irwin Naturals' Bold Leap: Cannabis, Psychedelics Drive Q3 Buzz Despite Falling Revenue & Surging Losses
Irwin Naturals Inc. (CSE:IWIN) (OTC:IWINF) (FRA: 97X), a nutraceutical company leveraging its brand into the cannabis and psychedelics sectors, reported its financial results for the third quarter of fiscal 2023, revealing revenue of $19.1 million, down from $22.0 million in the same period last year and $22.1 million in the previous quarter.
利用其品牌进入大麻和迷幻药领域的营养品公司欧文·自然公司(CSE: IWIN)(场外交易代码:IWINF)(FRA:97X)公布了2023财年第三季度的财务业绩,显示收入为1,910万美元,低于去年同期的2,200万美元和上一季度的2,210万美元。
"During the first three quarters of 2023, we successfully launched our branded licensing initiative in our cannabis sector," Sean Sand, CFO, stated. "Sales have exceeded our expectations and we look forward to continuing our licensing efforts in the space. We also continued to expand our mental health footprint through the acquisition of an industry-leading marketing and patient acquisition platform, Ketamine Media, enabling greater treatment availability and market expansion."
首席财务官肖恩·桑德表示:“在2023年前三个季度,我们在大麻领域成功启动了品牌许可计划。”“销售超出了我们的预期,我们期待继续在该领域开展许可工作。我们还通过收购行业领先的营销和患者获取平台Ketamine Media,继续扩大我们的心理健康足迹,从而提高治疗可用性和市场扩张。”
Q3 Financial Highlights
第三季度财务摘要
-
Gross profit was $7.8 million, which compares to $10.6 million in the third quarter of 2022.
-
Net loss amounted to $1.96 million, versus net loss of $583,000 in the same period last year.
-
Income from operations decreased $2.9 million from $0.6 million in Q3 2022 to a loss of $2.3 million in Q3 2023. The decline is primarily attributed to the continued startup costs related to the company's 2022 and 2023 acquisitions via Irwin Naturals Emergence.
-
In the third quarter, the company sold the assets of underperforming clinics and shifted its focus to clinics that are wholly owned and operated by Irwin Naturals Emergence.
-
As of June 30, the company had $70.86 million in total assets and $56.97 million in total liabilities, compared to $78.8 million and $48.5 million, respectively, on December 31, 2022.
-
毛利为780万美元,而2022年第三季度为1,060万美元。
-
净亏损为196万美元,而去年同期的净亏损为58.3万美元。
-
运营收入从2022年第三季度的60万美元减少了290万美元,至2023年第三季度的亏损230万美元。下降的主要原因是与该公司2022年和2023年通过Irwin Naturals Emergence进行收购相关的持续启动成本。
-
在第三季度,该公司出售了表现不佳的诊所的资产,并将重点转移到由Irwin Naturals Emergence全资拥有和运营的诊所上。
-
截至6月30日,该公司的总资产为7,086万美元,总负债为5,697万美元,而2022年12月31日分别为7,880万美元和4,850万美元。
Operational Highlights
运营亮点
During the first half of 2023, Irwin Naturals launched the first products to the continental cannabis market and signed ten brand licensing deals that will make THC-enhanced Irwin Naturals products available in places like California, Colorado, Mississippi, Michigan, New Mexico, Oregon, Oklahoma and Canada.
2023年上半年,Irwin Naturals向大陆大麻市场推出了第一批产品,并签署了十项品牌许可协议,将在加利福尼亚州、科罗拉多州、密西西比州、密西西比州、密歇根州、新墨西哥州、俄勒冈州、俄克拉荷马州和加拿大等地提供四氢大麻酚增强型Irwin Naturals产品。
Additionally, to date, the company owns and operates five mental health clinics and one advertising company specializing in ketamine treatments. It will continue to build upon this solid foundation and make the necessary investments to support our growth objectives within the psychedelics sector.
此外,迄今为止,该公司拥有并经营五家心理健康诊所和一家专门从事氯胺酮治疗的广告公司。它将继续在这个坚实的基础上再接再厉,进行必要的投资,以支持我们在迷幻药领域的增长目标。
Related Links:
相关链接:
Irwin Naturals Revenue Sluggish In Q2, Net Loss Grows YOY
Irwin Naturals第二季度收入低迷,净亏损同比增长
Irwin Naturals Launches Trio Of Cannabis Tinctures In California
Irwin Naturals 在加利福尼亚推出三款大麻酊剂
Photo: Courtesy of Yash Lucid via Pexels
照片:由 Yash Lucid 通过 Pexels 提供